merged_alzheimers-treatment-kisunla-donanemab.txt
<other>I need to carefully read through the article to find answers to each question based solely on the information provided.</other>

<question_number>1</question_number>
<answer>significant safety risks, including swelling and bleeding in the brain</answer>

<question_number>2</question_number>
<answer>it's slowing progress</answer>

<question_number>3</question_number>
<answer>There's no correlation in any of their studies between the removal of amyloid plaques and the clinical response in individual subjects</answer>

<question_number>4</question_number>
<answer>N/A</answer>

<question_number>5</question_number>
<answer>reflects the expectation that the patients can stop Kisunla after their plaques are cleared</answer>

<question_number>6</question_number>
<answer>might discourage patients from participating in trials for treatments that could be better</answer>

<question_number>7</question_number>
<answer>Kisunla is given monthly while Leqembi is given every two weeks</answer>

<question_number>8</question_number>
<answer>amyloid</answer>

<question_number>9</question_number>
<answer>Dr. Greicius</answer>

<question_number>10</question_number>
<answer>Trial participants with intermediate tau levels declined more slowly on donanemab than those with high levels</answer>